About NervGen
NervGen is a company based in Vancouver (Canada) founded in 2016. NervGen offers products and services including NVG-291 and NVG-300. NervGen operates in a competitive market with competitors including Tonix Pharma, Neuraptive, veriNOS pharmaceuticals, Ischemix and Proniras, among others.
- Headquarter Vancouver, Canada
- Stage Public
- SectorsHealthcare
- Website nervgen.com
- Social LinkedIn X Facebook YouTube
- Legal Name Nervgen Pharma Corp.
- Net Profit-$16.69 M (USD)-7.25as on Dec 31, 2024
- EBITDA-$17.27 M (USD)-40.93as on Dec 31, 2024
- Latest Funding Round$1.5M (USD), Grant
Oct 2022
- Investors
Products & Services of NervGen
NervGen offers a comprehensive portfolio of products and services, including NVG-291 and NVG-300.
Phase 1b/2a trial drug for spinal cord injury repair.
Preclinical drug for ischemic stroke and spinal cord injury.
Apps and channels of NervGen
its YouTube channel NervGen Pharma Corp. has 758 subscribers and 1 videos.
Videos from NervGen
The most watched videos on NervGen's YouTube channel, NervGen Pharma Corp. (758 subscribers). Click a video to play it here.
More on NervGen Pharma Corp..
Funding Insights of NervGen
- Total Rounds 7
- Last Round Grant — $1.5M
- First Round $1.5M
(Nov 2019)
- Investors Count 1
All 7 funding rounds of NervGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2022 | $1.5M | Grant | – | – | |
| Jul 2022 | $15.2M | Post-IPO | – | – | – |
| Dec 2021 | $651,815 | Post-IPO | – | – | – |
| Aug 2021 | $263,692 | Post-IPO | – | – | – |
| Jun 2021 | $2.19M | Post-IPO | – | – | – |
| Jun 2020 | $285,141 | Post-IPO | – | – | – |
| Nov 2019 | $1.5M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in NervGen
NervGen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Administers health care and support for military personnel and operations. | – | health.mil | Falls Church, United States |
Investor details for NervGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NervGen
31 people are tracked at NervGen (6 in leadership, 25 in board & advisors).
| Name | Role | Group |
|---|---|---|
Paul Brennan | CEO & President | Leadership |
Matthew McGuinness | Senior Director, Corporate Controller | Leadership |
Dan Mikol | Chief Medical Officer | Leadership |
Bill Adams | CFO | Leadership |
Judy Toews | Director, Pharmaceutical Development | Leadership |
Marc Depaul | Director Of Research & Nvg-291 Project Leader | Leadership |
Jeffrey Cummings | Advisor | Board & advisors |
Bruce Lamb | Advisor | Board & advisors |
George Perry | Advisor | Board & advisors |
Henrik Zetterberg | Advisor | Board & advisors |
Daniel Lammertse | Advisor | Board & advisors |
Jeffrey Cohen | Advisor | Board & advisors |
Randall Kaye | Director | Board & advisors |
Brian McAlister | Co-Founder & Advisor | Board & advisors |
Reisa Sperling | Advisor | Board & advisors |
Martin Farlow | Advisor | Board & advisors |
Brian Bayley | Director | Board & advisors |
Craig Thompson | Director | Board & advisors |
Michael Davis | Advisor | Board & advisors |
Jerry Silver | Scientific Advisor | Board & advisors |
11 more people are available in the full profile.
Complete people profiles for NervGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of NervGen
NervGen is a publicly listed company on the TSXV with ticker symbol NGEN in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Feb 2019
- Listed onTSX-V: NGEN
- Listed entityNervGen Pharma Corp.
- Exchange sectorHealth technology
- ISINCA64082X2032
- Share price5.15 CAD (+3% on the day) · 2026-03-17
- Market capitalisation409,907,859.00 CAD
- EPS (diluted, trailing year)-0.36 CAD
- Volume (last session)66,939
- Analyst consensusStrong buy
Financials of NervGen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | – | -24.0M CAD | -24.9M CAD |
| 2023 | – | -22.4M CAD | -17.6M CAD |
| 2022 | – | -20.7M CAD | -22.9M CAD |
| 2021 | – | -12.7M CAD | -12.8M CAD |
| 2020 | – | -11.2M CAD | -11.2M CAD |
Detailed financial statements for NervGen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of NervGen
4 dated milestones of NervGen across 6 years, from founding to its latest funding, stage changes and deals.
- Founded NervGen is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.5M.
- Funding Latest funding round, Grant, of $1.5M.
Competitors of NervGen
NervGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tonix Pharma, Neuraptive, veriNOS pharmaceuticals, Ischemix and Proniras, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tonixpharma.com | 2007 | New York, United States | $4.45M | 117 | Next-generation medicines for CNS and immunological disorders are developed. | |
| neuraptive.com | 2016 | Lafayette, United States | $12.5M | – | Therapeutic solution for the repair of cut and crushed peripheral nerves. | |
| verinos-pharma.com | 1998 | Wurzburg, Germany | $62.7M | – | Developer of therapeutics for retina and brain diseases | |
| ischemix.com | 2006 | Grafton, United States | $6.6M | – | Developer of cytoprotective therapy for traumatic brain injury | |
| proniras.com | 2018 | Seattle, United States | $11.23M | 2 | Small molecules are developed for seizures and brain injury treatment. | |
| edgetherapeutics.com | 2009 | New Providence, United States | $164.73M | 26 | Novel therapies for acute neurological conditions are developed and commercialized. | |
| neurexistherapeutics.com | 2020 | Aurora, United States | $605,000 | – | Neuroprotective therapeutic peptides are developed for brain disorder treatment. | |
| hiteck.com.cn | 2001 | Wuhan, China | – | – | Biological products including growth factor injections are developed and manufactured. |
Detailed competitors of NervGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NervGen
The website of NervGen (nervgen.com) receives about 19.6K visits a month.
- Monthly visits19.6K
▲ 3.6% vs previous month
Latest news on Nervgen
Complete news archive for NervGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to NervGen
10 companies that operate in the same segment as NervGen (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NervGen
NervGen was founded in 2016 and raised its 1st funding round 3 years after it was founded.
NervGen is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Paul Brennan is the current CEO of NervGen.
NervGen was founded in 2016 in Vancouver, Canada, and operates in the biotechnology sector focused on neural regeneration. Technology targeting protein tyrosine phosphatase sigma (PTPσ) is utilized to promote nerve repair. The lead candidate, NVG-291, an inhibitor of the PTPσ receptor, is currently undergoing clinical testing for spinal cord injury applications. Operations center on advancing therapies for conditions involving nerve damage.
NervGen's top competitors include Tonix Pharma, Neuraptive and Neurexis Therapeutics.
NervGen offers NVG-291 and NVG-300.
Yes, NervGen is publicly traded on TSXV under the ticker symbol NGEN.
NervGen has 1 investor. Key investors include Military Health.
NervGen operates through Nervgen Pharma Corp.